scholarly journals Complete Tumor Cell Necrosis

2020 ◽  
Author(s):  
Keyword(s):  
Tumor Cell ◽  
Cell Necrosis ◽  
Complete Tumor ◽  
Tumor Cell Necrosis

Sublytic complement inhibits sTNF-a induced tumor cell necrosis

2009 ◽  
Vol 46 (14) ◽  
pp. 2831-2832
Author(s):  
Lili Liu ◽  
Zhuoya Li ◽  
Michael Kirschfink
Keyword(s):  
Tumor Cell ◽  
Cell Necrosis ◽  
Tumor Cell Necrosis

Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells

2007 ◽  
Vol 62 (3) ◽  
pp. 491-498 ◽  
Author(s):  
Victor Adler ◽  
Wilbur Bowne ◽  
Ikram Kamran ◽  
Josef Michl ◽  
Fred K. Friedman ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Cancer Cells ◽  
Human Cancer ◽  
Cell Necrosis ◽  
Human Cancer Cells ◽  
Ras P21 ◽  
Phenotypic Reversion ◽  
Tumor Cell Necrosis

scholarly journals Herceptin Conjugates Linked by EDC Boost Direct Tumor Cell Death via Programmed Tumor Cell Necrosis

PLoS ONE ◽  
2011 ◽  
Vol 6 (8) ◽  
pp. e23270 ◽  
Author(s):  
Jiemiao Hu ◽  
Xinli Liu ◽  
Dennis Hughes ◽  
Francisco J. Esteva ◽  
Bolin Liu ◽  
...  
Keyword(s):  
Cell Death ◽  
Tumor Cell ◽  
Cell Necrosis ◽  
Tumor Cell Death ◽  
Tumor Cell Necrosis

scholarly journals NAD+ Treatment Induces Tumor Cell Necrosis by P2X7 Receptor‐Independent Pathways

2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Cuiping Zhao ◽  
Yunyi Hong ◽  
Jin Han ◽  
Weiliang Xia ◽  
Weihai Ying
Keyword(s):  
Tumor Cell ◽  
P2x7 Receptor ◽  
Cell Necrosis ◽  
Tumor Cell Necrosis

scholarly journals Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma

2019 ◽  
Vol 181 (2) ◽  
pp. K21-K27 ◽  
Author(s):  
Eva C Coopmans ◽  
Sebastiaan W F van Meyel ◽  
Kay J Pieterman ◽  
Jolique A van Ipenburg ◽  
Leo J Hofland ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Somatostatin Receptor ◽  
Cystic Degeneration ◽  
Tumor Control ◽  
Receptor Subtype ◽  
Cell Necrosis ◽  
New Treatment ◽  
Long Acting ◽  
Somatostatin Receptor Ligand ◽  
Tumor Cell Necrosis

Prolactinomas are the most commonly encountered pituitary adenomas in the clinical setting. While most can be controlled by dopamine agonists, a subset of prolactinomas are dopamine-resistant and very aggressive. In such tumors, the treatment of choice is neurosurgery and radiotherapy, with or without temozolomide. Here, we report a patient with an highly aggressive, dopamine-resistant prolactinoma, who only achieved biochemical and tumor control during pasireotide long-acting release (PAS-LAR) therapy, a second-generation somatostatin receptor ligand (SRL). Interestingly, cystic degeneration, tumor cell necrosis or both was observed after PAS-LAR administration suggesting an antitumor effect. This case shows that PAS-LAR therapy holds clinical potential in selective aggressive, dopamine-resistant prolactinomas that express somatostatin (SST) receptor subtype 5 and appears to be a potential new treatment option before starting temozolomide. In addition, PAS-LAR therapy may induce cystic degeneration, tumor cell necrosis or both in prolactinomas.

Sign in / Sign up

Export Citation Format

Share Document